Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK Centre

A Gibb; C Jones; A Bloor; S Kulkarni; T Illidge; K Linton; J Radford

Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK Centre

A Gibb, C Jones, A Bloor, S Kulkarni, T Illidge, K Linton, J Radford

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Haematologica
Volume	12
Publication status	Published - Oct 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Improving survival and reducing treatment damage in Hodgkin lymphoma.
Radford, J. (Corresponding participant) & Illidge, T. (Participant)
Impact: Health and wellbeing

Cite this

@article{f64ed88232df4247813e1b737f05db09,

title = "Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK Centre",

author = "A Gibb and C Jones and A Bloor and S Kulkarni and T Illidge and K Linton and J Radford",

year = "2012",

month = oct,

language = "English",

volume = "12",

journal = "Haematologica",

issn = "1592-8721",

publisher = "Ferrata Storti Foundation",

}

TY - JOUR

T1 - Brentuximab vedotin in refractory CD30+ lymphomas

T2 - a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK Centre

AU - Gibb, A

AU - Jones, C

AU - Bloor, A

AU - Kulkarni, S

AU - Illidge, T

AU - Linton, K

AU - Radford, J

PY - 2012/10

Y1 - 2012/10

M3 - Article

SN - 1592-8721

VL - 12

JO - Haematologica

JF - Haematologica

ER -

Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK Centre

UN SDGs

Impacts

Improving survival and reducing treatment damage in Hodgkin lymphoma.

Cite this